Drug recall · November 25, 2020
Metformin HCl Extended Release Tablets USP 500 mg recall
Why: CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Metformin HCl Extended Release Tablets USP 500 mg, Generic for : Glucophage XR, Pkg Size 100, Mfg: Time-Cap Labs, Inc.; Farmingdale, NY, NDC #: 68788-6932-1, Preferred Pharmaceuticals, Inc.
- Lots / codes
E0620F, Exp.12/31/2021; G2020M Exp., 04/30/2022
- Quantity
- 99 bottles (9990 Extended Release Tablets)
- Company
- Preferred Pharmaceuticals, Inc., Anaheim, CA
- Distribution
- Distributed to two physician's offices located in FL.
- Initiated
- November 1, 2020 · Voluntary: Firm initiated
- Classified
- November 14, 2020
- Reported
- November 25, 2020
- Ended
- May 20, 2024
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Metformin
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.